NASDAQ:SPPI
Delisted
Spectrum Pharmaceuticals Stock News
$1.03
+0 (+0%)
At Close: Oct 30, 2023
GUANGZHOU, China , Jan. 14, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced the publication of the Phase I clinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD
Qylur Awarded SBIR Phase II Contract for Tactical AI Spectrum Classifier Systems (TASCS)
02:18pm, Wednesday, 02'nd Oct 2024
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile S
Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)
02:18pm, Wednesday, 02'nd Oct 2024
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile S
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
08:48am, Monday, 19'th Aug 2024
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which h
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
07:10am, Thursday, 27'th Jun 2024
Press Release STALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core sympto
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
05:00am, Tuesday, 25'th Jun 2024
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that it has com
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respi
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for
NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug
09:19am, Tuesday, 28'th Nov 2023
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, wi
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
01:15am, Monday, 13'th Nov 2023
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting
St Andrews, UK – 2nd October 2023 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respirator
NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug
08:16am, Monday, 21'st Aug 2023
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collabor
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
06:30pm, Thursday, 27'th Jul 2023
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet
BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Sharehol
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pha